3/24/08 - 182 Words
Allergan has launched a Phase 2 clinical trial to evaluate Botulinum Toxin Type A for the treatment of Cervical Dystonia. Due to the low incidence of the disease – roughly 125,000 cases in North America – and that patients suffering with CD symptoms initially seek treatment from physicians who may not have much exposure to the disease, this condition can be misdiagnosed as Parkinson’s, Wry Neck, Cerebral Palsy, or Muscular Dystrophy.
In an effort to reach these physicians and other healthcare professionals who have had limited experience with CD, Allergan has initiated The CD Research Awareness Initiative to facilitate diagnosis and provide an option for patients who would otherwise not seek or be able to afford treatment.
The study is open to male and female patients, ages 18 – 75, who have never received treatment with botulinum toxin or any serotype for treatment of Cervical Dystonia or for any other condition. The duration of the study is variable per patient; between 50 and 60 weeks.
For more information about The CD Research Awareness Initiative or the clinical research study call (866) 245-4763 or visit www.mycdstudy.com.
